Literature DB >> 24655692

Improving diagnosis and treatment of women with angina pectoris and microvascular disease: the iPOWER study design and rationale.

Eva Prescott1, Steen Zabell Abildstrøm2, Ahmed Aziz3, Noel Bairey Merz4, Ida Gustafsson5, Julian Halcox6, Henrik Steen Hansen3, Peter Riis Hansen7, Jens Kastrup8, Marie Michelsen2, Naja Dam Mygind8, Peter Ong9, Adam Pena7, Annika Rosengren10, Udo Sechtem9, Peter Søgaard11.   

Abstract

BACKGROUND: The iPOWER study aims at determining whether routine assessment of coronary microvascular dysfunction (CMD) in women with angina and no obstructive coronary artery disease is feasible and identifies women at risk.
METHODS: All women with angina referred to invasive angiographic assessment in Eastern Denmark are invited to join the study according to in- and exclusion criteria. Assessment includes demographic, clinical and psychosocial data, symptoms, electrocardiogram, blood- and urine samples and transthoracic echocardiography during rest and dipyridamol stress with measurement of coronary flow reserve (CFR) by Doppler of the left anterior descending artery. In substudies CMD will be assessed by positron emission tomography, peripheral endothelial function, magnetic resonance imaging-and computed tomography derived myocardial perfusion scans, angiographic corrected TIMI frame counts, advanced echocardiographic modalities at rest and during stress, and invasive measures of CFR and coronary vascular reactivity. The study will include 2000 women who will be followed for 5 years for cardiovascular outcomes.
RESULTS: By May 2013, 1685 women have been screened, 759 eligible patients identified, 530 contacted, and 299 (56%) agreed to participate. Among the first 50 patients, Doppler CFR was successfully measured in 49 (98%).
CONCLUSIONS: Among women with suspected ischemic heart disease and no obstructive coronary artery disease, non-invasive Doppler CFR is feasible as a routine assessment. The study will provide information on methods to diagnose CMD and determine the prognostic value of routine non-invasive assessment of microvascular function. Future study will provide women identified with CMD participation in interventional substudies designed to test treatment strategies.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24655692     DOI: 10.1016/j.ahj.2014.01.003

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  15 in total

Review 1.  Noninvasive Imaging to Evaluate Women With Stable Ischemic Heart Disease.

Authors:  Lauren A Baldassarre; Subha V Raman; James K Min; Jennifer H Mieres; Martha Gulati; Nanette K Wenger; Thomas H Marwick; Chiara Bucciarelli-Ducci; C Noel Bairey Merz; Dipti Itchhaporia; Keith C Ferdinand; Carl J Pepine; Mary Norine Walsh; Jagat Narula; Leslee J Shaw
Journal:  JACC Cardiovasc Imaging       Date:  2016-04

Review 2.  Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy.

Authors:  Jenna Dean; Sherwin Dela Cruz; Puja K Mehta; C Noel Bairey Merz
Journal:  Nat Rev Cardiol       Date:  2015-05-26       Impact factor: 32.419

Review 3.  Coronary Microvascular Dysfunction: A Practical Approach to Diagnosis and Management.

Authors:  Daria Frestad Bechsgaard; Eva Prescott
Journal:  Curr Atheroscler Rep       Date:  2021-07-16       Impact factor: 5.113

Review 4.  Coronary Microvascular Dysfunction in Patients With Systemic Lupus Erythematosus and Chest Pain.

Authors:  Ashley S Manchanda; Alan C Kwan; Mariko Ishimori; Louise E J Thomson; Debiao Li; Daniel S Berman; C Noel Bairey Merz; Caroline Jefferies; Janet Wei
Journal:  Front Cardiovasc Med       Date:  2022-04-15

Review 5.  Clinical usefulness of novel serum and imaging biomarkers in risk stratification of patients with stable angina.

Authors:  George Tsaknis; Iraklis Tsangaris; Ignatios Ikonomidis; Argirios Tsantes
Journal:  Dis Markers       Date:  2014-06-19       Impact factor: 3.434

Review 6.  Role of echocardiography in the management of cardiac disease in women.

Authors:  Wan Joo Shim
Journal:  J Cardiovasc Ultrasound       Date:  2014-12-26

7.  Coronary microvascular function and myocardial fibrosis in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study.

Authors:  Naja Dam Mygind; Marie Mide Michelsen; Adam Pena; Abbas Ali Qayyum; Daria Frestad; Thomas Emil Christensen; Adam Ali Ghotbi; Nynne Dose; Rebekka Faber; Niels Vejlstrup; Philip Hasbak; Andreas Kjaer; Eva Prescott; Jens Kastrup
Journal:  J Cardiovasc Magn Reson       Date:  2016-11-04       Impact factor: 5.364

8.  Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography: a randomised controlled trial.

Authors:  Michelle C Williams; Amanda Hunter; Anoop Shah; Valentina Assi; Stephanie Lewis; Kenneth Mangion; Colin Berry; Nicholas A Boon; Elizabeth Clark; Marcus Flather; John Forbes; Scott McLean; Giles Roditi; Edwin Jr van Beek; Adam D Timmis; David E Newby
Journal:  Heart       Date:  2017-02-28       Impact factor: 5.994

9.  Effect of ACE-inhibition on coronary microvascular function and symptoms in normotensive women with microvascular angina: A randomized placebo-controlled trial.

Authors:  Marie Mide Michelsen; Anna Bay Rask; Elena Suhrs; Kristoffer Flintholm Raft; Nis Høst; Eva Prescott
Journal:  PLoS One       Date:  2018-06-08       Impact factor: 3.240

10.  Coronary Microvascular Function and Cardiovascular Risk Factors in Women With Angina Pectoris and No Obstructive Coronary Artery Disease: The iPOWER Study.

Authors:  Naja Dam Mygind; Marie Mide Michelsen; Adam Pena; Daria Frestad; Nynne Dose; Ahmed Aziz; Rebekka Faber; Nis Høst; Ida Gustafsson; Peter Riis Hansen; Henrik Steen Hansen; C Noel Bairey Merz; Jens Kastrup; Eva Prescott
Journal:  J Am Heart Assoc       Date:  2016-03-15       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.